HB9 Lentiviral Activation Particles (h): sc-402097-LAC

MNX1 encodes the homeobox transcription factor HB9, a sequence-specific DNA-binding regulator that controls developmental gene expression programs in ventral spinal cord and motor neuron specification, as well as pancreatic lineage differentiation. HB9 integrates with broader homeobox and neuronal differentiation networks to coordinate cell fate decisions, axon guidance programs, and maturation-associated transcriptional cascades. Dysregulated MNX1 expression or altered HB9 activity has been associated with neurodevelopmental defects and with oncogenic transcriptional reprogramming in select malignancies, where it can influence proliferation and lineage identity. These biology links make MNX1/HB9 a useful node for studying transcriptional control of differentiation, neuronal circuit development, and context-dependent gene regulation.

HB9 Lentiviral Activation Particles (h) address this need by packaging the complete synergistic activation mediator (SAM) transcriptional activation system into transduction-ready, high-titer lentiviral particles, enabling efficient MNX1 upregulation across a broader range of human cell types.

HB9 Lentiviral Activation Particles (h) deliver all functional components of the synergistic activation mediator (SAM) system via lentiviral transduction. The system comprises three particle preparations co-transduced into target cells: one encoding catalytically inactive dCas9 (D10A and N863A mutations) fused to the VP64 transactivation domain with a blasticidin resistance gene; one encoding the MS2-p65-HSF1 fusion protein with a hygromycin resistance gene; and one encoding a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers with a puromycin resistance gene. Following lentiviral transduction and genomic integration of the expression cassettes, the SAM components are stably expressed and assemble at the target locus within the proximal promoter region upstream of the MNX1 transcriptional start site, where VP64, p65, and HSF1 act cooperatively to recruit endogenous transcriptional machinery and drive sustained upregulation of endogenous HB9 expression. The use of nuclease-inactive dCas9 avoids the introduction of double-strand DNA breaks and preserves the native MNX1 genomic locus and regulatory architecture.

The lentiviral format offers several practical advantages: stable genomic integration supports heritable activation across cell divisions; high-titer particle preparations eliminate the need for in-house viral production; and compatibility with primary, non-dividing, and transfection-resistant cell types expands experimental accessibility. Successful transduction can be confirmed and enriched through triple antibiotic selection using puromycin, hygromycin, and blasticidin.

For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.